Thyroid
Thyroglobulin antibodies
The second autoimmune thyroid marker, and occasionally the only one that turns positive.
Thyroglobulin antibodies target thyroglobulin, the protein your thyroid uses as scaffolding to build hormone. They are the second marker of autoimmune thyroid disease alongside TPO antibodies, and they occasionally turn positive when TPO antibodies do not, which is the main reason to include them. Notably, a 2024 meta-analysis found selenium supplementation lowered TPO antibodies but found no significant change in thyroglobulin antibodies.
What it actually measures
To build thyroid hormone, your thyroid needs scaffolding, and thyroglobulin is it.
It is a large protein your thyroid produces and stores, onto which iodine is attached and from which finished hormone is eventually cut free. Think of it as the workbench rather than the product.
Thyroglobulin antibodies are antibodies your immune system has made against that workbench.
That makes them the second marker of autoimmune thyroid activity, alongside TPO antibodies, which target the enzyme that does the attaching. Two antibodies, two different targets, the same underlying process.
TPO antibodies are the more commonly positive of the pair and are generally considered the more sensitive marker for autoimmune thyroid disease.
So why order this one at all? Because a minority of people with genuine autoimmune thyroid disease are thyroglobulin antibody positive while TPO antibody negative, and in those people this is the only marker that shows what is happening.
When it matters, and when it does not
The honest framing is that this is a supporting marker rather than a leading one, and it earns its place in specific situations.
The first is completeness. If autoimmune thyroid disease is genuinely suspected and TPO antibodies come back negative, thyroglobulin antibodies are what catch the subset that TPO alone misses.
The second is a technical one worth knowing about even though it applies to a specific group. Thyroglobulin itself is used as a tumour marker in monitoring after thyroid cancer treatment, and thyroglobulin antibodies interfere with that measurement, causing falsely low or undetectable results. A 2011 clinical review in the Journal of Clinical Endocrinology and Metabolism reported antibodies detectable in roughly 20 percent of differentiated thyroid cancer patients, and concluded every specimen needs antibody testing to authenticate the thyroglobulin result.
The population data is worth having, and it makes the hierarchy between the two antibodies explicit. NHANES III, published in the Journal of Clinical Endocrinology and Metabolism in 2002, measured thyroid antibodies in 17,353 people aged 12 and over. Thyroglobulin antibodies were positive in about 10.4 percent and TPO antibodies in about 11.3 percent.
Critically, that analysis found thyroglobulin antibodies alone, in the absence of TPO antibodies, were not significantly associated with thyroid disease, while TPO antibodies were.
That is the honest reason this marker is a supporting one. A positive thyroglobulin antibody with negative TPO is common and, in that population data, was not by itself associated with disease.
A 2005 review in Best Practice and Research Clinical Endocrinology and Metabolism examined thyroid antibodies in euthyroid subjects, meaning people with normal thyroid function, which is the state where antibodies most often turn up unexpectedly.
There is an interesting divergence in the treatment evidence too. The 2024 meta-analysis in Thyroid covering 35 studies of selenium in Hashimoto thyroiditis found TPO antibodies decreased across 29 cohorts, while specifically reporting no significant change in thyroglobulin antibodies.
So the two antibodies do not behave identically in response to intervention, which is a genuine finding rather than a curiosity. It suggests they are not simply two readings of the same thing.
For prognosis, the better data sits with TPO. A 2022 cohort of 940 euthyroid TPO-positive women found 7.4 percent developed hypothyroidism, with higher baseline titres in those who progressed.
What moves it
Down: not reliably, and that is worth stating plainly. The selenium evidence that lowers TPO antibodies specifically did not move thyroglobulin antibodies. Titres fluctuate on their own over time, and treating the number as a target is not well supported for this marker.
Up: the autoimmune process itself, which is the honest answer. Pregnancy and the postpartum period shift antibody activity. Some medications including interferon and amiodarone. Very high iodine intake in susceptible people. And thyroid injury or surgery, which can release thyroglobulin and provoke a response.
The honest hedge
I am not a doctor and I am not diagnosing anyone.
A positive thyroglobulin antibody result on its own, with entirely normal thyroid function and negative TPO antibodies, is a finding with less established prognostic weight than a positive TPO. That is worth knowing before it causes alarm.
The reasonable response to it is the same as for TPO: monitoring on a schedule your doctor sets, rather than treatment of a number.
I would also not want anyone chasing this titre downward. The selenium evidence, which is the best supplement evidence in this area, moved TPO antibodies and specifically did not move thyroglobulin antibodies. Treating this number as a target is not supported.
There is one situation where this test genuinely changes what another result means, and that is thyroid cancer monitoring, where antibody presence interferes with thyroglobulin measurement. That is entirely a specialist context.
For everyone else, the useful role is completeness: if the autoimmune question is being asked seriously, ask it with both antibodies rather than one.
So. What to actually do.
Tonight, at no cost. Check whether your last thyroid result includes any antibodies at all. Most panels stop at TSH, so for many people neither antibody has ever been measured.
Order both antibodies if the autoimmune question is real. TPO antibodies first, since they are the more sensitive marker, with thyroglobulin antibodies alongside to catch the subset TPO misses.
Run them with the hormones, not instead. A thyroid panel with free T4 and free T3 tells you function, and antibodies tell you process. Both from one draw.
If positive, switch to monitoring. Thyroid function on a schedule your doctor sets is what converts a positive result from a worry into an early warning.
Do not chase the titre with supplements. The selenium evidence that moves TPO antibodies specifically did not move this one.
Mention it if you are pregnant or planning to be. Thyroid antibody status matters in pregnancy and warrants closer monitoring.
Take the whole picture to a good functional medicine doctor, or an endocrinologist where a diagnosed condition is on the table.
You are not defined by an antibody titre. You are a system where an immune response found a second target, and knowing that is better than not knowing it.
Your body is not broken. It is blocked. And sometimes the block shows up on the second marker after the first came back clean, which is exactly why asking with both is worth one extra line.
Go check whether antibodies were ever ordered at all.
Read these alongside it
The more sensitive antibody, and the one with the prognostic data.
Why the two antibodies respond differently to the same intervention.
Function alongside process, from the same draw.
TSH with the hormones, and antibodies alongside.
The active hormone, and the one TSH cannot see.
Know what your numbers mean
Occasional notes on the markers worth measuring, what the research supports, and where it stops. No hype, and you can leave any time.
Questions
What are thyroglobulin antibodies?›
What is the difference between TPO and thyroglobulin antibodies?›
Should I test thyroglobulin antibodies?›
Does selenium lower thyroglobulin antibodies?›
What does a positive thyroglobulin antibody mean?›
Why do thyroglobulin antibodies matter for thyroid cancer monitoring?›
Can thyroid antibodies be positive with normal thyroid function?›
References
- Hollowell JG, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). The Journal of Clinical Endocrinology and Metabolism. 2002. PMID 11836274
- Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). The Journal of Clinical Endocrinology and Metabolism. 2011. PMID 21917876
- Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Practice and Research. Clinical Endocrinology and Metabolism. 2005. PMID 15826919
- Huwiler VV, et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid. 2024. PMID 38243784